The Companion Diagnostics Development Services Market is projected to grow at an annualized rate of ~5%, till 2030.

 

Roots Analysis has done a detailed report on Companion Diagnostics Development Services Market, 2020-2030 covering key aspects of the industry and identifying future growth opportunities

 

 

To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

Key Market Insights

§  Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic tests

§  Currently, a variety of services are available across the entire diagnostics development supply chain, including assays based on a wide range of analytical techniques, especially in the developed geographies

§  Numerous pharmaceutical players are actively seeking to enter into partnership with companion diagnostics service providers, in order to leverage the latter’s expertise in this field

§  The rise in interest in this field is reflected in the number of partnerships established in the recent past, involving both international and indigenous stakeholders, and focused on a variety of end objectives

§  In order to achieve an edge over the contemporary competition, companies engaged in this domain are increasingly focusing on the integration of advanced service offerings in their respective portfolios

§  The value chain involves drug and diagnostics developers, service providers, along with other important stakeholders, each having a discrete set of priorities and requirements

§  Given the growing demand for precision medicine, the companion diagnostics services market is expected to witness a double digit growth; the opportunity is likely to be distributed across different regions and techniques

§  In the long-term, growth in the market is anticipated to be driven by the clinical studies based on novel tumor markers, which have been identified as promising biological targets for development of companion diagnostics

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY


3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Evolution of Personalized Medicine

 

3.3.       Overview of Companion Diagnostics

3.3.1.    Development of Companion Diagnostics

3.3.2.    Analytical Techniques Used in Companion Diagnostic Tests

3.3.2.1. Immunohistochemistry

3.3.2.2. In situ Hybridization

3.3.2.3. Polymerase Chain Reaction

3.3.2.4. DNA Sequencing / Next Generation Sequencing

3.3.3.    Advantages of Companion Diagnostics

3.4.       Applications of Companion Diagnostics across Different Therapeutic Areas

3.4.1.    Oncology

3.4.2.    Infectious Diseases

3.4.3.    Neurological Disorders

3.5.       Regulatory Review and Approval Process for Companion Diagnostics

3.6.       Existing Challenges

3.7.       Future Roadmap

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companion Diagnostics Service Providers: Overall Market Landscape

4.2.1     Analysis by Type of Service Offered

4.2.2.    Analysis by Type of Analytical Technique

4.2.3.    Analysis by Regulatory Accreditation / Certification

 

4.3.       Companion Diagnostics Service Providers: Developer Landscape

4.3.1     Analysis by Year of Establishment

4.3.2     Analysis by Company Size

4.3.3     Analysis by Geographical Location

4.3.4     Grid Representation: Analysis by Type of Service Offered, Company Size, and Geographical Location

4.3.5     World Map Representation: Analysis by Geography

 

5.         COMPANY PROFILES

5.1.       Chapter Overview

 

5.2.       Key Players in North America

5.2.1.    Asuragen

5.2.1.1. Recent Developments and Future Outlook

 

5.2.2.    Covance

5.2.2.1. Recent Developments and Future Outlook

 

5.2.3.    Geneuity

5.2.3.1. Recent Developments and Future Outlook

 

5.2.4.    MD Biosciences

5.2.4.1. Recent Developments and Future Outlook

 

5.2.5.    ResearchDx

5.2.5.1. Recent Developments and Future Outlook

 

5.3.       Players in Europe

5.3.1.    Almac Diagnostic Services

5.3.1.1. Recent Developments and Future Outlook

 

5.3.2.    Leica Biosystems

5.3.2.1. Recent Developments and Future Outlook

 

5.3.3.    R-Biopharm

5.3.3.1. Recent Developments and Future Outlook

 

5.3.4.    Tepnel Pharma Services

5.3.4.1. Recent Developments and Future Outlook

 

5.4.       Key Players in Asia-Pacific

5.4.1.    BARD1 Life Sciences

5.4.1.1. Recent Developments and Future Outlook

 

5.4.2.    BioMarCare Technologies

5.4.2.1. Recent Developments and Future Outlook

 

5.4.3.    Gencurix

5.4.3.1. Recent Developments and Future Outlook

 

5.4.4.    Macrogen

5.4.4.1. Recent Developments and Future Outlook

           

6.         PARTNERSHIPS AND COLLABORATIONS

6.1        Chapter Overview

6.2        Partnership Models

6.3        List of Partnerships and Collaborations

6.3.1     Analysis by Year of Partnership

6.3.2     Analysis by Type of Partnership

6.3.3     Analysis by Type of Analytical Technique

6.3.4     Analysis by Type of Therapeutic Area

6.3.5     Analysis by Year of Partnership and Type of Partner

6.3.6     Analysis by Type of Partnership and Type of Partner

6.3.7     Most Active Players: Analysis by Number of Partnerships

6.3.8     Popular Analytical Techniques: Analysis by Number of Partnerships

6.3.9     Regional Analysis

6.3.10   Intercontinental and Intracontinental Agreements

 

7.         LIKELY PARTNER ANALYSIS

7.1.       Chapter Overview

7.2.       Scope and Methodology

7.3.       Scoring Criteria and Key Assumptions

7.4.       Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease

7.4.1.    Companies Working on the Amyloid Beta Biomarker

7.4.1.1. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials

 

7.4.2.    Companies Working on the Tau Biomarker

7.4.2.1. World Map Representation: Tau Biomarker Focused Clinical Trials

 

7.5.       Likely Partners for Companion Diagnostics Service Providers: Breast Cancer

7.5.1.    Companies Working on the BRCA Biomarker

7.5.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

 

7.5.2.    Companies Working on the HER Biomarker

7.5.2.1. World Map Representation: HER Biomarker Focused Clinical Trials

 

7.5.3.    Companies Working on the HR Biomarker

7.5.3.1. World Map Representation: HR Biomarker Focused Clinical Trials

 

7.5.4.    Companies Working on the PD-L1 Biomarker

7.5.4.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

 

7.6.       Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer

7.6.1.    Companies Working on the BRAF Biomarker

7.6.1.1. World Map Representation: BRAF Biomarker Focused Clinical Trials

 

7.6.2.    Companies Working on the EGFR Biomarker

7.6.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

 

7.6.3.    Companies Working on the KRAS Biomarker

7.6.3.1. World Map Representation: KRAS Biomarker Focused Clinical Trials

 

7.6.4.    Companies Working on the MSI Biomarker

7.6.4.1. World Map Representation: MSI Biomarker Focused Clinical Trials

 

7.6.5.    Companies Working on the NRAS Biomarker

7.6.5.1. World Map Representation: NRAS Biomarker Focused Clinical Trials

 

7.7.       Likely Partners for Companion Diagnostic Service Providers: HIV

7.7.1.    Companies Working on the CCR5 Biomarker

7.7.1.1. World Map Representation: CCR5 Biomarker Focused Clinical Trials

 

7.8.       Likely Partners for Companion Diagnostics Service Providers: Lung Cancer

7.8.1.    Companies Working on the ALK Biomarker

7.8.1.1. World Map Representation: ALK Biomarker Focused Clinical Trials

 

7.8.2.    Companies Working on the EGFR Biomarker

7.8.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

 

7.8.3.    Companies Working on the PD-L1 Biomarker

7.8.3.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

 

7.8.4.    Companies Working on the ROS Biomarker

7.8.4.1. World Map Representation: ROS Biomarker Focused Clinical Trials

 

7.9.       Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD

7.9.1.    Companies Working on the AST Biomarker

7.9.1.1. World Map Representation: AST Biomarker Focused Clinical Trials

 

7.10.     Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer

7.10.1.  Companies Working on the BRCA Biomarker

7.10.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

 

7.10.2.  Companies Working on the CA-125 Biomarker

7.10.2.1. World Map Representation: CA-125 Biomarker Focused Clinical Trials

7.11.     Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer

7.11.1.  Companies Working on the PTEN Biomarker

7.11.1.1. World Map Representation: PTEN Biomarker Focused Clinical Trials

 

 

16.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more